INMB_OUT_1 [2025-04-03 07:19:48 -0400] 2676 Bytes | 804 tokens | Cum: 804 tkns (10.05% of 8k)
==========================================================================

We're scouting for winners today. Its 7:19:47 AM on Thu Apr 03, 2025 -0400 and I'm looking at INmune Bio (INMB) up to 9.79 from 8.07

Help me investigate to see if its got potential or just another dud. So, I pulled together a bunch of data for you to look over real fast.

--- COMPANY PROFILE ---
Company: INmune Bio (INMB)
IPO: 2019-02-04 (6 Years Ago)
Market Cap: $172,234,003
Shares Outstanding: 22,930,000
Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange: XNAS
Description: INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.

Here's the first list of news for INmune Bio:

C1 - Apr-01-25 07:00AM - INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study
C2 - Mar-28-25 03:04AM - INmune Bio Inc (INMB) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges
C3 - Mar-27-25 08:15PM - INmune Bio, Inc. (INMB) Q4 2024 Earnings Call Transcript
C4 - Mar-27-25 08:15PM 04:05PM - INmune Bio Inc. Announces Year End 2024 Results and Provides a Business Update
C5 - Mar-24-25 08:00AM - INmune Bio Inc. to Report Fourth Quarter 2024 Financial Results and Provide Corporate Update on March 27, 2025
C6 - Mar-21-25 01:15PM - Undercovered Dozen: INmune Bio, Primerica, First Quantum, Pinnacle West +
C7 - Mar-02-25 09:28AM - Why INmune Bio, Inc. (INMB) is Skyrocketing So Far in 2025
C8 - Feb-12-25 09:51AM - INmune Bio price target raised to $23 from $22 at Scotiabank

Prior AI Reports for INMB:
1. 2025-03-19 – Score: 45 – Target: 9.0000 – Highs: 8.4300 / 8.5000 / 8.18
company-shows-strong-past-faces-current-challenges

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on INmune Bio (INMB)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

INMB_OUT_3 [2025-04-03 07:19:49 -0400] 1108 Bytes | 325 tokens | Cum: 1131 tkns (14.14% of 8k)
==========================================================================

Showing C1 (chunk 1 of 9): C1:
**INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study**
Date: Apr-01-25 07:00AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/04/01/3053159/0/en/INmune-Bio-Inc-Presents-Baseline-Demographics-and-Disease-Profiles-of-Participants-in-the-MINDFuL-Phase-II-Study.html

April 01, 2025 07:00 ET| Source:INmune Bio, Inc.INmune Bio, Inc.

MINDFuL Phase II Blinded, Randomized, Placebo-Controlled Data Anticipated June 2025

Boca Raton, Florida, April 01, 2025 (GLOBE NEWSWIRE) --INmune Bio, Inc.(NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, is presenting a poster at the annual International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disord

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

INMB_OUT_5 [2025-04-03 07:19:49 -0400] 907 Bytes | 278 tokens | Cum: 1411 tkns (17.64% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-01T21:48:32Z - INmune Bio Presents MINDFuL Trial Data At AD/PD 2025...
A2 - 2025-04-01T21:51:00Z - INmune Bio Presents MINDFuL Trial Data At AD/PD 2025...
A3 - 2025-04-01T16:43:00Z - INmune Bio Presents Baseline Data From MINDFuL Phase II Trial In Early Alzheimer's Disease...
A4 - 2025-04-01T11:31:57Z - INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL P...
A5 - 2025-04-01T11:18:13Z - INmune Bio presents early Alzheimer's trial data at AD/PD By Investing.com...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

INMB_OUT_7 [2025-04-03 07:19:56 -0400] 1100 Bytes | 319 tokens | Cum: 1732 tkns (21.65% of 8k)
==========================================================================

Showing A1 (chunk 1 of 2): A1:
**INmune Bio Presents MINDFuL Trial Data At AD/PD 2025**Date: 2025-04-02Source: {'uri': 'finanzen.ch', 'dataType': 'news', 'title': 'finanzen.ch'}URL: https://www.finanzen.ch/nachrichten/aktien/inmune-bio-presents-mindful-trial-data-at-ad-pd-2025-1034538997(RTTNews) - INmune Bio, Inc. (INMB), a clinical-stage immunology company, Tuesday announced that it is presenting findings from its MINDFuL Phase II trial at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) 2025 in Vienna.

The trial focuses on early Alzheimer's disease (AD) patients with confirmed biomarkers of inflammation.

The study enrolled 208 patients, categorized as mild cognitive impairment (MCI, 44%) or mild AD (mAD, 56%), with an average age of 72. Participants met criteria for at least one inflammation biomarker and were randomized 2:1 to receive XPro™ or placebo for 23 weeks via weekly subcu

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

INMB_OUT_9 [2025-04-03 07:19:56 -0400] 905 Bytes | 289 tokens | Cum: 2156 tkns (26.95% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-07-19T21:53:47Z - Inmune Bio re-elects directors, ratifies auditor - Investing.com
B2 - 2024-07-12T11:37:58Z - Zura Bio initiates exchange offer for warrants By Investing.com - Investing.com
B3 - 2024-05-30T12:00:00Z - INmune Bio Inc. to Join Russell 3000® Index
B4 - 2024-05-09T20:05:00Z - INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update
B5 - 2024-03-28T20:01:00Z - INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update
B6 - 2024-03-26T20:01:00Z - INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

INMB_OUT_11 [2025-04-03 07:19:59 -0400] 631 Bytes | 177 tokens | Cum: 2335 tkns (29.19% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Inmune Bio re-elects directors, ratifies auditor - Investing.com**Date: Unknown DateSource: Unknown SourceURL: https://www.investing.com/news/company-news/inmune-bio-reelects-directors-ratifies-auditor-93CH-3527788Inmune Bio, a biopharmaceutical company, held its annual stockholders meeting, resulting in the re-election of its board of directors and the ratification of its independent auditor for the upcoming fiscal year.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

INMB_OUT_13 [2025-04-03 07:20:00 -0400] 1096 Bytes | 278 tokens | Cum: 2662 tkns (33.27% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-27 8-K Item 2.02 Results of Oper and Fin Cond.

On March 27, 2025, INmune Bio Inc. announced its financial results for the year ended December 31, 2024 and provided a business update. The full text of the press release issued in connection with the announcement is furn...

S2 - 2025-03-27 10-K ITEM 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our financial statements and notes thereto appearing else...

S3 - 2025-03-04 8-K Item 7.01. Regulation FD Disclosure.

INmune Bio Inc. (the Company) has prepared a slide deck that the Company intends to use in presentations from time to time (the Presentation). The Presentation is furnished as Exhibit 99.1 to this Curr Report on Form 8-K.

The information...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

INMB_OUT_15 [2025-04-03 07:20:06 -0400] 1040 Bytes | 261 tokens | Cum: 2925 tkns (36.56% of 8k)
==========================================================================

Showing S1 (chunk 1 of 1): S1:
Item 2.02 Results of Operations and Financial Condition.

On March 27, 2025, INmune Bio Inc. announced its financial results for the year ended December 31, 2024 and provided a business update. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by specific reference in such a filing....

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

INMB_OUT_17 [2025-04-03 07:20:19 -0400] 4208 Bytes | 1193 tokens | Cum: 4209 tkns (52.61% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+---------------------+----------------------+-------------------------+------------------------+
| Volume: 241,220 | Perf Month: -0.37% | Option/Short: Yes / Yes | Sales Y/Y TTM: -90.97% |
+---------------------+----------------------+-------------------------+------------------------+
| Avg Volume: 383.36K | Perf Quarter: 73.55% | Short Float: 34.20% | ROE: -119.83% |
+---------------------+----------------------+-------------------------+------------------------+
| Rel Volume: 0.63 | Index: RUT | Short Ratio: 14.54 | ROI: -130.12% |
+---------------------+----------------------+-------------------------+------------------------+
| RSI (14): 50.74 | Market Cap: 185.05M | Short Interest: 5.58M | Sales Surprise: - |
+---------------------+----------------------+-------------------------+------------------------+
| ATR (14): 0.67 | Shs Outstand: 22.28M | Beta: 1.64 | EPS Surprise: 26.99% |
+---------------------+----------------------+-------------------------+------------------------+
| SMA20: 1.10% | Shs Float: 16.30M | Sales Q/Q: -100.00% | P/E: - |
+---------------------+----------------------+-------------------------+------------------------+
| SMA50: -4.31% | Inst Own: 27.06% | Sales past 5Y: 303.04% | Earnings: Mar 27 AMC |
+---------------------+----------------------+-------------------------+------------------------+
| SMA200: 18.69% | Insider Own: 28.90% | Employees: 22 | |
+---------------------+----------------------+-------------------------+------------------------+
| Perf Week: 4.40% | Insider Trans: 0.00% | Debt/Eq: 0.01 | |
+---------------------+----------------------+-------------------------+------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 14000, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -42082000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 8.07
Average Volume: 258683.09
30-Day High: 8.86
30-Day Low: 7.19

[Detailed Financials: TTM 2024]
- Total Assets: $39,562,000.0
- Total Liabilities: $7,465,000.0
- Total Equity: $32,097,000.0
- Current Assets: $22,662,000.0
- Current Liabilities: $7,221,000.0

[Income Statement: TTM 2024]
- Revenue: $14,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -2.11

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-224,000

[Detailed Financials: FY 2024]
- Total Assets: $39,562,000.0
- Total Liabilities: $7,465,000.0
- Total Equity: $32,097,000.0
- Current Assets: $22,662,000.0
- Current Liabilities: $7,221,000.0

[Income Statement: FY 2024]
- Revenue: $14,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -2.11

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-224,000
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

INMB_OUT_19 [2025-04-03 07:20:23 -0400] 676 Bytes | 167 tokens | Cum: 4640 tkns (58.00% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

INMB_IN_21 [2025-04-03 07:20:23 -0400] 126 Bytes | 29 tokens | Cum: 4749 tkns (59.36% of 8k)
==========================================================================

====================================
[2025-04-03 07:20:23] # Analysis Completed
Elapsed Time: 35.86 seconds